OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2023-12-31-accounts

Haemochromatosis UK Trustees’ Annual Report & Accounts 2023

HAEMOCHROMATOSIS UK TRUSTEES’ ANNUAL REPORT & ACCOUNTS

Haemochromatosis UK Trustees’ Annual Report and Accounts

For the year ending 31 December 2023 Published April 2024 © Haemochromatosis UK www.haemochromatosis.org.uk

Statutory Information

We are Haemochromatosis UK. Registered as Charity number 1001307 and SCO41701. Company Limited by Guarantee No. 2541361.

Registered office

The Flaxmill, Flaxmill Lane, Pinchbeck, Lincolnshire, PE11 3YP

Regulators

Charity Commission for England and Wales (Charity No. 1001307) The Office of the Scottish Charity Regulator (Charity No. SCO41701) Companies House (Company Limited by Guarantee No. 2541361)

Independent Financial Examiner

Community Accounting Plus Units 1 and 2, Northwest 41 Talbot Street Nottingham NG1 5GL

Trustees

Dr Heidi Fuller (appointed 12 November 2023), Interim Co-Chair Serena ter Kuile (appointed 12 November 2023), Interim Co-Chair Rodger Houghton, Finance Trustee Kevin King, Legal Trustee Dr Florian Jaeckle (appointed 12 November 2023) Katy Burns MBE, Chair of Trustees (resigned 12 November 2023) Catherine Wiggins (resigned 12 November 2023)

2

HAEMOCHROMATOSIS UK TRUSTEES’ ANNUAL REPORT & ACCOUNTS @

CONTENTS

----- Start of picture text -----
|||| |---|---|---| |Section Contents|Page| |2|A message from the Chief Executive|5| |3|Trustees’ report for 2023|6| |4|Governance|9| |5|Haemochromatosis UK Objectives, strategies and activities|11| |6|Independent examiner’s report to the Trustees of Haemochromatosis UK 13| |7|Accounts|15|

----- End of picture text -----

3

HAEMOCHROMATOSIS UK TRUSTEES’ ANNUAL REPORT & ACCOUNTS

2. A MESSAGE FROM THE CHIEF EXECUTIVE

It’s been an amazing and busy 2023!

Despite a range of cost of living pressures, we’ve grown our membership base by almost 20% during 2023. Our clinician education programme is busier than ever, with our Royal College of General Practitioners and Royal College of Nursing accredited eLearning resources both securing re-accreditation and growing healthcare professional usage. Our medical research programme, over-seen by an expanded Clinical & Research Advisory Panel, is also growing as we seek clinical solutions to many of the problems commonly experienced by people with GH.

Our genetic testing service continued it’s exciting growth trajectory. What started almost 3 years ago as a tentative toe-in-the-water has developed into a core service, helping families understand their genetic risk of iron overload and facilitating research into the often under-reported prevalence of the condition. We regularly receive positive feedback on the life changing impact of this service and our pro-active efforts to provide screening to communities at risk:

“I was a participant in your first testing project in Derry, Northern Ireland two years ago...as a result of my diagnosis, several of my siblings and their children have been diagnosed…so I am very grateful that you have initiated this testing programme.”

Haemochromatosis UK now conducts more HFE genetic tests most weeks than the entire NHS. We continue to press for better access to testing and a pro-active, preventative healthcare approach by the NHS to the condition. It’s important to us that we deliver this service to a very high standard, something which is recognised in a net promoter score of 94% by people who have received a test from us. This is tribute to the diligence of our staff team, who work hard to deliver the majority of test results within 2 weeks in a format which is readily understood, complemented by a counselling appointment with our specialist nurses. This feedback from someone who recently completed a test and received support and advice from our specialist nurses Diogo and Victoria is representative:

“I must say I’m amazed by Haemochromatosis UK. You are a really sharp, smart and effective outfit, especially in the way that you link your excellent advice service so smartly to your research and advocacy. “

2023 saw our first multi-channel TV, radio and billboard awareness campaign. With the help of local businesses in Northern Ireland we launched a £300k awareness campaign that garnered great feedback from the community as well as screening over 100 people who would otherwise been unaware of their risks of iron overload. We hope to do more of this in other parts of the UK, but funding is always a challenge.

4

HAEMOCHROMATOSIS UK TRUSTEES’ ANNUAL REPORT & ACCOUNTS

During the year we doubled-down on our commitment to our volunteers and the vital role they play in many aspects of our work. This was recognised independently with the award of Investing In Volunteers accreditation, a significant milestone in our efforts to professionalise our approach to volunteering across the charity’s activities.

Early in 2023 we launched our new GH Buddy Scheme. This matches up people seeking information and ongoing support following a recent diagnosis with our amazing trained volunteer Buddies. We’ve been taken aback at just how well received this new service has been. Almost 100 people have been buddied in this first year and we look forward with excitement to expanding the service in 2024.

We continue to press “the powers that be” for improvements in care for people affected by genetic haemochromatosis. Our advocacy through the All-Party Parliamentary Group on Genetic Haemochromatosis at Westminster continues. It’s now complimented by similar initiatives at Stormont and Holyrood.

Our work in Northern Ireland has been particularly well-received. In March 2023, we published our NI Cost of Illness report which builds upon the health economics model we developed in 2021 with YHEC for the UK as a whole. Revising the model to incorporate the results of our NI screening programme reveals that the costs to the NHS in Northern Ireland by not pro-actively diagnosing the condition are disproportionate, something that has spurred the Northern Ireland Blood Transfusion Service to improve donor registration processes to enable faster and easier GH donor registration, mirroring arrangements we secured in England and Wales in 2021/2.

In June we launched our new smartphone app, MyIron+. We were thrilled to see thousands of people with GH install the app to help manage blood test results, appointments and to access our range of trusted information resources. Within 6 months of launch we had measured 5 times as many app users as we had projected for the whole year, a pattern of growth that has continued into 2024.

Our charity receives no NHS or government funding. Everything we do is powered by donations. And so we are especially thankful to our financial supporters, for everything they do - helping us, to help others.

Thank you to everyone who has helped us in 2023 – we look forward to 2024 with excitement!

Neil McClements, Chief Executive Officer January 2024

5

HAEMOCHROMATOSIS UK TRUSTEES’ ANNUAL REPORT & ACCOUNTS

3. TRUSTEES’ REPORT FOR 2023

The trustees, who are directors for the purposes of company law, present the annual report together with the financial statements of the charitable company for the year ended 31 December 2023.

The Trustees:

Dr Heidi Fuller (appointed 12 November 2023), Interim Co-Chair Serena ter Kuile (appointed 12 November 2023), Interim Co-Chair Rodger Houghton, Finance Trustee Kevin King, Legal Trustee Dr Florian Jaeckle (appointed 12 November 2023) Katy Burns MBE, Chair of Trustees (resigned 12 November 2023) Catherine Wiggins (resigned 12 November 2023)

Background

Genetic haemochromatosis (GH) is a condition that leads to a build-up of iron in the body to toxic levels. In turn this causes a wide range of symptoms and follow on conditions, some of which can be very serious or indeed, in the worst cases, fatal.

Haemochromatosis UK (HUK) is a patient led membership-based charity and patient organisation. At year-end HUK had almost 2,900 paid-up members and over 2,700 clinician associates. The charity links thousands of people affected by GH through events, social media and other activities.

HUK has four key objectives :

In this report, we report progress with these objectives during 2023 and outline plans and aspirations for the coming year.

The Trustees follow the Charity Commission’s guidance on public benefit when planning and reviewing spending, activities and budgets. Many of the trustees have GH themselves, which ensures that we do not lose sight of our priorities. We also recognise that having GH is not a prerequisite to join the Board. We seek to draw upon a wide range of talents and skills, both within and beyond the GH community, to ensure that the Board is effective and focussed in supporting the charity’s continuing development.

6

HAEMOCHROMATOSIS UK TRUSTEES’ ANNUAL REPORT & ACCOUNTS

It’s important to note that the charity’s financial position remains sound, despite the significant and continuing challenges to community fundraising brought by the Covid pandemic. We continue to focus on stewarding the charity’s financial resources to ensure the long-term sustainability of the organisation whilst delivering much-need, effective services to the GH community. Our Annual Financial Statements set out the financial position in more detail on the following pages.

Trust grants

This year, we have enjoyed further increased support from charitable trusts and donations from family foundations totalling £197,246.

The Trustees would like to extend their grateful thanks and public acknowledgment to our supporters:

Corporate donations

We gratefully acknowledge the support of the following donors for their support during 2023:

An important thank you message

The trustees extend their grateful thanks to all the volunteers, members, donors, fundraisers, activists, advisers and other supporters who have made a contribution over the year. There are so many individuals who have helped develop the life of our charity – too many to mention by name. It is difficult to convey the importance of what you do for us and for people affected by genetic haemochromatosis in a few words; we thank you all sincerely.

7

HAEMOCHROMATOSIS UK TRUSTEES’ ANNUAL REPORT & ACCOUNTS

Statement of Fundraising Regulator and Fundraising Preference Service Compliance

Donors to our charity can be assured that we comply with the regulatory standards for fundraising. We are registered with the Fundraising Regulator and are committed to the Fundraising Promise and adherence to the Code of Fundraising Practice. This report covers the requirements charities must follow as set out in the Charities Act 2016.

To raise funds for the charity we apply to grant-making bodies, encourage volunteer participation in external fundraising events, ask for regular and spontaneous donations through online appeals, and receive donations in memory and in lieu of gifts. Our staff work in-house to help us deliver fundraising initiatives. We aim to ensure any external fundraisers, professional or voluntary we engage observe the highest standards in terms of fundraising practice, including compliance with the Code of Fundraising Practice and the charity’s own policies. Our Fundraiser is a Diploma qualified member of the Chartered Institute of Fundraising.

We are registered with the Fundraising Regulator and comply with all the relevant standards set out in the Code of Fundraising Practice.

We occasionally use third-party partners to help us raise funds (for example the Big Give), particularly where we do not have the expertise in-house. We have safeguards in place when working with partners so that we protect our supporters and the reputation of our charity. All donations are accepted and processed in line with the charity’s published Donations Policy.

We aim to respond to all complaints relating to our fundraising activities within 28 days. Complaints are dealt with in-line with our fundraising complaints policy. Any serious complaints are dealt with by our CEO and Trustees so that they can consider lessons learnt. The Trustees also consider an annual report about complaints, from the CEO.

Our website provides our contact details to the public, in the event that an individual wishes to make a complaint. In 2023, we had no fundraising complaints and so there were no complaints to report to the Fundraising Regulator.

We are also signed up to the Fundraising Preference Service (FPS) to enable individuals to opt out from receiving fundraising communications from us. In 2023, we received no requests from the FPS for action.

We publish our external policies publicly on our website here: https://www. - haemochromatosis.org.uk/our policies These include our Safeguarding Policy. In addition to this policy we have an agreed operating procedure to protect vulnerable people. Our fundraisers (both staff and partners) are familiarised with the code of conduct to ensure that it is applied properly and everyone fundraising for the charity undertakes mandatory safeguarding training and assessment, annually.

8

HAEMOCHROMATOSIS UK TRUSTEES’ ANNUAL REPORT & ACCOUNTS

4. GOVERNANCE

Trustees are responsible in law for the financial and strategic management of the charity. They are accompanied on the board by Board Observers, who are “trustees-intraining”.

Board members are expected to attend all Board meetings and the charity’s annual conference and AGM, contribute meaningfully to decision making, and to act in accordance with good practice guidance issued by the Charity Commission and Companies House.

In 2021, the charity enhanced its governance with the introduction of Board Observers. These people bring specific skills to the board in an advisory capacity and are “trusteesin-training”. After a suitable period of time, the Board and Observer may consider, but are not obliged to undertake, a progression to full trusteeship. Board Observers attend all board meetings but do not have voting rights and are not directors of the charity’s company limited by guarantee. However, they are encouraged to participate fully in the life of the charity and the board’s activities. During 2023, Serena ter Kuile, Dr Heidi Fuller and Dr Florian Jaeckle progressed from Board Observership to Trusteeship at the invitation of the board.

When a Trustee or Board Observer vacancy arises, it is advertised widely in accordance with Charity Commission best practice guidance. This includes on our own website, eBulletin and social media channels, plus external recruitment forums including ICAEW Volunteers, CharityJobs, Reach Volunteering, Law Society Volunteering, LinkedIn, Women On Boards, the Young Trustees Movement and elsewhere. Each new trustee/ board observer is provided with an induction training pack, which includes a guide to the legal and practical responsibilities of being a trustee/observer. Formal training with NCVO in the role and legal responsibilities of a trustee is also provided. All board members must undertake safeguarding training, annually.

Our record with the commission is at www.charitycommission.gov.uk and can be found by searching on this site using charity number 1001307.

The Executive

The Trustees delegate responsibility for day-to-day operations to the Chief Executive, in accordance with a formally documented Scheme of Delegation.

The Chief Executive is supported by a small part-time staff team, comprised of Advanced Nurse Practitioner, Information & Advisory Nurse, Philanthropy Manager, Finance Controller/Book-keeper and Charity Administrator. The team represents 4 fulltime equivalent post-holders.

9

HAEMOCHROMATOSIS UK TRUSTEES’ ANNUAL REPORT & ACCOUNTS

Risk Management

Haemochromatosis UK recognises the importance of understanding and managing risk. As such, the Board of Trustees conducts a review of the major risks to which the charity is exposed at each board meeting. As part of this process, a risk register has been established and is updated at least quarterly in order to identify and evaluate the risks faced and formulate a response.

Where appropriate, systems or procedures have been established to mitigate the risks the charity faces. Policies and procedures are periodically reviewed to ensure that they continue to meet the needs of the charity. Responsibility for risk assessment and day-today risk management is defined in the charity’s scheme of delegation.

Significant external risks to funding have led to the development of a strategic plan which will allow for the diversification of funding and activities. Internal control risks are minimised by the implementation of procedures for authorisation of all financial transactions. Risks to operations due to Covid-19 are monitored and implemented in accordance with prevailing UK government guidance.

Procedures and training are in place to ensure compliance with safeguarding best practices and the health and safety of staff, volunteers and beneficiaries.

Strategic Planning

The charity worked throughout 2022 to review and revise its organisational strategy. The organisational strategy was formally endorsed and adopted in early 2023 by the board. An overview has been published online here : https://www.haemochromatosis.org.uk/ strategy-2023-to-2028.

10

HAEMOCHROMATOSIS UK TRUSTEES’ ANNUAL REPORT & ACCOUNTS

5. HAEMOCHROMATOSIS UK OBJECTIVES, STRATEGIES AND ACTIVITIES

Objects and aims

To provide for persons with hereditary haemochromatosis or associated diseases (hereinafter called “the Diseases”) help with those problems (including but not limited to diagnosis, medical care, treatment and financial burden) resulting from the Diseases and to provide such other charitable relief as the Society may think fit;

Objectives, strategies and activities

HUK undertakes four key activities :

Public benefit

The charity’s Trustees have given due consideration to the Charity Commission for England & Wales’ published guidance on the public benefit requirement under the Charities Act 2011. Our programme of activities also conforms to the charity’s charitable objectives and aims.

We work to support anyone affected by genetic haemochromatosis, irrespective of age, gender, ethnicity or race, religion, sexual orientation or genetic status. In particular, our information, advice and helpline services are available to the general public free of charge. Our annual review illustrates several initiatives to advance patient safety through improved clinician education and our wider influencing work, in the public interest, to raise awareness of the needs of the genetic haemochromatosis community through engagement with elected representatives, policymakers and the public at large.

As such, the work carried out by Haemochromatosis UK is consistent with charitable purposes as identified in the Charities Act 2011 (The advancement of health or saving of lives).

The trustees confirm that they have complied with the requirements of section 17 of the Charities Act 2011 to have due regard to the public benefit guidance published by the Charity Commission for England and Wales.

11

HAEMOCHROMATOSIS UK TRUSTEES’ ANNUAL REPORT & ACCOUNTS

Statement of Trustees’ Responsibilities

The trustees (who are also the directors of Haemochromatosis UK for the purposes of company law) are responsible for preparing the trustees’ report and the financial statements in accordance with the United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) and applicable law and regulations.

Company law requires the trustees to prepare financial statements for each financial year. Under company law the trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the trustees are required to:

The trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charitable company’s transactions and disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Small companies provision statement

This report has been prepared in accordance with the small companies regime under the Companies Act 2006.

Approved by the Board on 8th March 2024.

Dr Heidi Fuller Interim Co-Chair March 2024

Serena ter Kuile Interim Co-Chair March 2024

12

HAEMOCHROMATOSIS UK TRUSTEES’ ANNUAL REPORT & ACCOUNTS

6. INDEPENDENT EXAMINER’S REPORT TO THE TRUSTEES OF HAEMOCHROMATOSIS UK

Independent examiner’s report to the Trustees of Haemochromatosis UK (‘the Company’)

I report to the charity trustees on my examination of the accounts of the company for the year ended 31 December 2023.

Responsibilities and basis of report

As the charity’s trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 (‘the 2006 Act’).

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity’s accounts as carried out under section 145 of the Charities Act 2011 (‘the 2011 Act’). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner’s statement

Since the Company’s gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member and Fellow of the Association of Charity Independent Examiners, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

  1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or

  2. the accounts do not accord with those records; or

  3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a ‘true and fair’ view which is not a matter considered as part of an independent examination; or

  4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities [applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)].

13

HAEMOCHROMATOSIS UK TRUSTEES’ ANNUAL REPORT & ACCOUNTS

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

John O’Brien MSc, FAIA, FCCA, FCIE, employee of Community Accounting Plus Fellow of the Association of Charity Independent Examiners

Units 1 & 2 North West 41 Talbot Street Nottingham NG1 5GL

26th March 2024

14

HAEMOCHROMATOSIS UK TRUSTEES’ ANNUAL REPORT & ACCOUNTS

ACCOUNTS

15

HAEMOCHROMATOSIS UK TRUSTEES’ ANNUAL REPORT & ACCOUNTS

Haemochromatosis UK

Statement of Financial Activities for the Year Ended 31 December 2023 (Including Income and Expenditure Account and Statement of Total Recognised Gains and Losses)

Note Unrestricted
funds
Restricted
funds
Total
2023
Total
2022
£
£
£
£
Income and endowments from:
Donations and legacies
3
Charitable activities
4
Investment income
2		 144,118
-
144,118
201,420
219,644
54,798
274,442
234,546
5,138
-
5,138
840
Total income 368,900
54,798
423,698
436,806
Expenditure on:
Charitable activities
6		 (376,516)
(17,569)
(394,085) (457,303)
Total expenditure (376,516)
(17,569)
(394,085) (457,303)
Net (expenditure)/income
Net movement of funds		 (50,646)
37,229
29,613
(20,497)
(7,616)
37,229
29,613
(20,497)
Reconciliation of funds:
Total funds brought forward
Total funds carried forward
11		 306,069
70,259
376,328
396,825
298,453
107,488
405,941
376,328

All of the charity’s activities derive from continuing operations during the above two periods. The funds breakdown for the period is shown in note 11.

16

HAEMOCHROMATOSIS UK TRUSTEES’ ANNUAL REPORT & ACCOUNTS

Haemochromatosis UK

Statement of Financial Activities for the Year Ended 31 December 2023 (Including Income and Expenditure Account and Statement of Total Recognised Gains and Losses)

These are the figures for the previous accounting period and are included for comparative purposes

Note Unrestricted
funds
Restricted
funds
Total
2022
£
£
£
Income and endowments from:
Donations and legacies
3
Charitable activities
4
Investment income
2		 201,420
-
201,420
96,726
137,820
234,546
840
-
840
Total income 298,986
137,820
436,806
Expenditure on:
Charitable activities
6
Total expenditure
Net (expenditure)/income
Transfers between funds
Net movement of funds
Reconciliation of funds:
Total funds brought forward
Total funds carried forward
11		 (349,632)
(107,671)
(457,303)
(349,632)
(107,671)
(457,303)
(50,646)
30,149
(20,497)
4,811
(4,811)
-
(45,835)
25,338
(20,497)
351,904
44,921
396,825
306,069
70,259
376,328

17

HAEMOCHROMATOSIS UK TRUSTEES’ ANNUAL REPORT & ACCOUNTS

Haemochromatosis UK (Registration number: 02541361) Balance Sheet as at 31 December 2023

Notes 2023 2022
£ £
Current assets
Debtors
8
Cash at bank and in hand		 4,328
422,791		 13,246
378,762
Creditors: amounts falling due within one year
9		 427,119
(21,178)		 392,008
(15,680)
Net assets 405,941 376,328
Funds of the charity:
Restricted income funds
Restricted funds 107,488 70,259
Unrestricted income funds
Unrestricted funds 298,453 306,069
Total charity funds
11		 405,941 376,328

For the financial year ending 31 December 2023 the charity was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors’ responsibilities:

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

The financial statements on pages 16 to 31 were approved by the trustees, and authorised for issue on 8th March 2024 and signed on their behalf by:

Serena ter Kuile Trustee

Dr Heidi Fuller Trustee

18

HAEMOCHROMATOSIS UK TRUSTEES’ ANNUAL REPORT & ACCOUNTS

Haemochromatosis UK

Notes to the Financial Statements for the Year Ended 31 December 2023

1 Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)) (issued in October 2019)

Basis of preparation

Haemochromatosis UK meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

Going concern

The financial statements have been prepared on a going concern basis.

The trustees assess whether the use of going concern is appropriate i.e. whether there are any material uncertainties related to events or conditions that may cast significant doubt on the ability of the charity to continue as a going concern. The trustees make this assessment in respect of a period of one year from the date of approval of the financial statements.

Exemption from preparing a cash flow statement

The charity opted to early adopt Bulletin 1 published on 2 February 2016 and have therefore not included a cash flow statement in these financial statements.

Income and endowments

Voluntary income including donations, gifts, legacies and grants that provide core funding or are of a general nature is recognised when the charity has entitlement to the income, it is probable that the income will be received and the amount can be measured with sufficient reliability.

19

HAEMOCHROMATOSIS UK TRUSTEES’ ANNUAL REPORT & ACCOUNTS

Haemochromatosis UK

Notes to the Financial Statements for the Year Ended 31 December 2023

Donations and legacies

Donations are recognised when the charity has been notified in writing of both the amount and settlement date. In the event that a donation is subject to conditions that require a level of performance by the charity before the charity is entitled to the funds, the income is deferred and not recognised until either those conditions are fully met, or the fulfilment of those conditions is wholly within the control of the charity and it is probable that these conditions will be fulfilled in the reporting period.

Grants receivable

Grants are recognised when the charity has an entitlement to the funds and any conditions linked to the grants have been met. Where performance conditions are attached to the grant and are yet to be met, the income is recognised as a liability and included on the balance sheet as deferred income to be released.

Expenditure

All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a basis consistent with the use of resources, with central staff costs allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset’s use. Other support costs are allocated based on the spread of staff costs.

Charitable activities

Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Taxation

The charity is considered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.purposes.

20

HAEMOCHROMATOSIS UK TRUSTEES’ ANNUAL REPORT & ACCOUNTS

Haemochromatosis UK

Notes to the Financial Statements for the Year Ended 31 December 2023

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the charity will not be able to collect all amounts due according to the original terms of the receivables.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other shortterm highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the charity does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Fund structure

Unrestricted income funds are general funds that are available for use at the trustees’ discretion in furtherance of the objectives of the charity.

Designated funds are unrestricted funds set aside for specific purposes at the discretion of the trustees.

Restricted income funds are those grants for use in a particular area or for specific purposes, the use of which is restricted to that area or purpose.

Pensions and other post retirement obligations

The charity operates a defined contribution pension scheme for employees. The assets of the scheme are held separately from those of the charity. Pension costs charges in the Statement of Financial Activities represent the contributions payable by the charity during the year.

21

HAEMOCHROMATOSIS UK TRUSTEES’ ANNUAL REPORT & ACCOUNTS

Haemochromatosis UK

Notes to the Financial Statements for the Year Ended 31 December 2023

2 Investment income

2 Investment income
Unrestricted
funds Total Total
General 2023 2022
£ £ £
Interest receivable and similar income
Interest receivable on bank deposits 5,138 5,138 840

3 Income from donations and legacies

Donations and legacies;
Donations from companies, trusts and
similar proceeds
Donations from individuals
Grants, including capital grants;
Grants from other charities
Grants from companies		 Unrestricted funds
Total
Total
Designated
General
2023
2022
£
£
£
£
-
-
-
17,396
-
85,183
85,183
-
33,985
20,950
54,935
3,000
1,000
4,000
184,024
36,985
107,133
144,118
201,420

4 Income from charitable activities

Unrestricted funds Restricted Total Total
Designated General funds 2023 2022
£ £ £ £ £
Grants & donations - - 53,128 53,128 58,569
Consultancy fees 434 - 50 484 48,443
Membership subscriptions - 87,039 - 87,039 69,042
Merchandise - 1,411 1,533 2,944 8,341
Sundry income - (31) 87 56 -
Genetic testing 81,997 - - 81,997 50,151
Corporate sponsorship 20,000 1,121 - 21,121 -
Gift aid - 27,673 - 27,673 -
102,431 117,213 54,798 274,442 234,546

22

HAEMOCHROMATOSIS UK TRUSTEES’ ANNUAL REPORT & ACCOUNTS

Haemochromatosis UK

Notes to the Financial Statements for the Year Ended 31 December 2023

5 Grants & donations

5Grants & donations
Astor Foundation
BCH
Blunt Trust
Boots plc
Caf Donate
Callendar Charitable Trust - Glasgow screening
Cambrideshire commerce
Chapman Trust
De Laszio Foundation
DMG Roper Trust
Doris Field Charitable Trust
FB Coales No 4 Family Trust
Forrester Family Trust
Guy Fawkes Charitable Trust
Harrow Trust
JK Foundation
JRC
Lascelles Chart Trust
M Boal Charitable Trust
Michael Cornish Charitable Trust
Much Loved
National Lottery Northern Ireland
Northcott Devon Foundation
Oakdale Trust
Robert Luff Foundation
Shears Foundation
Society for Endocrinology
Stripe Fundraising
Tesco
The Ardwick Trust
The Batchworth Trust
UKH Foundation
Zedra Trust
Other donations		 Unrestricted
funds
Restricted
funds
Total
£
£
£
1,000
-
1,000
1,000
-
1,000
1,000
-
1,000
-
9,978
9,978
850
-
850
1,000
-
1,000
3,000
4,000
7,000
1,000
-
1,000
10,000
-
10,000
-
150
150
1,000
-
1,000
-
2,500
2,500
-
5,000
5,000
2,500
-
2,500
500
-
500
2,500
-
2,500
-
500
500
2,000
-
2,000
-
2,500
2,500
-
1,000
1,000
1,656
-
1,656
1,500
8,500
10,000
250
250
500
-
2,000
2,000
-
10,000
10,000
20,000
-
20,000
485
-
485
722
-
722
-
1,000
1,000
200
-
200
-
5,000
5,000
5,000
-
5,000
5,000
-
5,000
81,955
750
82,705
144,118
53,128
197,246

23

HAEMOCHROMATOSIS UK TRUSTEES’ ANNUAL REPORT & ACCOUNTS

Haemochromatosis UK Notes to the Financial Statements for the Year Ended 31 December 2023

6 Expenditure on charitable activities

Accountancy
Advertising/ Promotional
Bank charges
Equipment & computer costs
External events
Dues & subscriptions
Hosted events
Insurance
Legal & professional
Materials stock
Offce / General admin
Phone costs
Premises costs
Printing, postage & stationery
Publications
Raising funds
Recruitment
Rent
Software
Staff benefts
Training
Travel & accommodation
Trustees expenses
Wages, NI & pension
Genetic testing
Medical Research
Merchandise cost
Utilities
App fees
Collection fees		 Unrestricted
General
funds
Unrestricted
Designated
funds
Restricted
funds
Total
2023
Total
2022
£
£
£
£
£
-
9,425
-
9,425
11,773
6,005
7,351
182
13,538
20,823
-
72
-
72
81
258
11,159
-
11,417
3,311
947
3,363
-
4,310
5,290
-
4,523
-
4,523
3,137
3,296
4,601
-
7,897
10,180
-
404
-
404
1,417
-
1,828
-
1,828
5,706
-
787
-
787
3,214
294
2,118
2,923
5,335
1,141
500
1,723
-
2,223
-
-
-
-
-
13,855
10,490
20,869
-
31,359
26,534
-
-
-
-
17,840
-
2,131
-
2,131
590
-
313
-
313
41
-
4,762
-
4,762
-
-
12,988
-
12,988
29,370
-
1,434
-
1,434
2,699
2,546
2,697
-
5,243
6,436
828
14,697
79
15,604
22,210
-
518
-
518
-
56,310
128,321
14,385
199,016
178,968
35,607
3,512
-
39,119
76,657
-
-
-
-
16,030
-
6,419
-
6,419
-
-
2,877
-
2,877
-
-
4,921
-
4,921
-
-
5,622
-
5,622
-
117,081
259,435
17,569 394,085 457,303

24

HAEMOCHROMATOSIS UK TRUSTEES’ ANNUAL REPORT & ACCOUNTS

Haemochromatosis UK Notes to the Financial Statements for the Year Ended 31 December 2023

7 Staff costs

The aggregate payroll costs were as follows:

The aggregate payroll costs were as follows:
Staff costs during the year were:
Wages and salaries
Social security costs
Pension costs		 2023
£
2022
£
176,679
163,464
18,271
11,443
4,066
4,061
199,016
178,968

Information on staff costs for the previous period is unavailable.

The monthly average number of persons (including senior management team) employed by the charity during the year was as follows:

2023 2022
No No
Average number of employees 4 4

3 (2022 - 3) of the above employees participated in the Defined Contribution Pension Schemes.

Contributions to the employee pension schemes for the year totalled £4,066 (2022 - £4,061).

No employee received emoluments of more than £60,000 during the year.

The total employee benefits of the key management personnel of the charity were £64,930 (2022 - £67,749).

8 Debtors

Trade debtors
Prepayments
Accrued income		 2023
£
2022
£
1,583
884
2,745
8,816
-
3,546
4,328
13,246

25

HAEMOCHROMATOSIS UK TRUSTEES’ ANNUAL REPORT & ACCOUNTS

Haemochromatosis UK

Notes to the Financial Statements for the Year Ended 31 December 2023

9 Creditors: amounts falling due within one year

Trade creditors
Other taxation and social security
Accruals		 2022
£
2021
£
14,707
8,105
4,456
6,784
2,015
791
21,178
15,680

10 Charity status

The charity is a company limited by guarantee and consequently does not have share capital. Each of the trustees is liable to contribute an amount not exceeding £1 towards the assets of the charity in the event of liquidation.

The principal place of business is: The Flaxmill Flaxmill Lane Pinchbeck Spalding PE11 3YP

26

HAEMOCHROMATOSIS UK TRUSTEES’ ANNUAL REPORT & ACCOUNTS

Haemochromatosis UK

Notes to the Financial Statements for the Year Ended 31 December 2023

11 Funds

Unrestricted funds
General
General
Designated
Education & Awareness
Genetic Testing
Project Mavis
MyIron+
Medical Research
Total Unrestricted funds
Restricted funds
Information & Support
Education & Awareness
Northern Ireland Community
Fund
Scottish Wellbeing
Irish Travellers Project
Medical Research
Wales Initiative
Forrester Family Trust
Helpline
Campaigning & Advocacy
Total restricted funds
Total funds		 Balance at
1 January
2023
Incoming
resources
Resources
expended
Transfers
Balance at
31 December
2023
£
£
£
£
£
142,191
229,484
(259,435)
(86,809)
25,431
163,878
22,485
(6,541)
-
179,822
-
103,931
(110,540)
6,609
-
-
13,000
-
52,200
65,200
-
-
-
3,000
3,000
-
-
-
25,000
25,000
163,878
139,416
(117,081)
86,809
273,022
306,069
368,900
(376,516)
-
298,453
2,847
13,545
(14,645)
-
1,747
46,068
-
-
-
46,068
500
8,500
-
9,000
11,589
-
(2,924)
-
8,665
454
-
-
-
454
-
4,000
-
-
4,000
8,801
-
-
-
8,801
-
5,000
-
-
5,000
-
13,103
-
-
13,103
-
10,650
-
-
10,650
70,259
54,798
(17,569)
-
107,488
376,328
423,698
(394,085)
-
405,941

27

HAEMOCHROMATOSIS UK TRUSTEES’ ANNUAL REPORT & ACCOUNTS

Haemochromatosis UK Notes to the Financial Statements for the Year Ended 31 December 2023

The specific purposes for which the funds are to be applied are as follows:

28

HAEMOCHROMATOSIS UK TRUSTEES’ ANNUAL REPORT & ACCOUNTS

Haemochromatosis UK

Notes to the Financial Statements for the Year Ended 31 December 202

Balance at Balance at
1 January Incoming Resources 31 December
2022 resources expended Transfers 2022
£ £
£		 £ £
Unrestricted funds
General
General 238,008 216,304 (312,121) - 142,191
Designated
Education & Awareness 113,896 82,682 (32,700) - 163,878
GH Education - - (4,811) 4,811 -
113,896 82,682 (37,511) 4,811 163,878
Total unrestricted funds 351,904 298,986 (349,632) 4,811 306,069
Restricted
Information & Support 2,347 500 - - 2,847
Education & Awareness 1,000 49,100 (4,032) - 46,068
GH Education 4,811 - - (4,811) -
Northern Ireland Community Fund 500 - - - 500
Scottish Wellbeing 11,589 - - - 11,589
Irish Travellers Project - 9,500 (9,046) - 454
Wales Initiative 8,801 - - - 8,801
Volunteer training 705 - (705) - -
Breaking Down Barriers 10,585 - (10,585) - -
Genetic Testing - 76,657 (76,657) - -
Total restricted funds 40,338 135,757 (101,025) (4,811) 70,259
Total funds 392,242 434,743 (450,657) - 376,328

29

HAEMOCHROMATOSIS UK TRUSTEES’ ANNUAL REPORT & ACCOUNTS

Haemochromatosis UK

Notes to the Financial Statements for the Year Ended 31 December 2023

12 Analysis of net assets between funds

Current assets
Current liabilities
Total net assets		 Unrestricted
General
Designated
Restricted
2023
Total funds
£
£
£
£
46,609
273,022
107,488
427,119
(21,178)
-
-
(21,178)
25,431
273,022
107,488
405,941
Current assets
Current liabilities
Total net assets		 Unrestricted
General
Designated
Restricted
2022
Total funds
£
£
£
£
157,871
163,878
70,259
392,008
(15,680)
-
-
(15,680)
142,191
163,878
70,259
376,328

13 Fees payable to independent examiner

During the period, the fees payable (excluding VAT) to the charity’s independent examiner Community Accounting Plus are analysed as follows:

Independent examination 2023
2022
£
£
1,135
1,116

30

HAEMOCHROMATOSIS UK TRUSTEES’ ANNUAL REPORT & ACCOUNTS

Haemochromatosis UK

Notes to the Financial Statements for the Year Ended 31 December 2023

14 Taxation

The charity is a registered charity and is therefore exempt from taxation.

15 Trustees’ remuneration and expenses

No trustees, nor any persons connected with them, have received any remuneration from the charity during the year.

No trustees have received any other benefits from the charity during the year.

15 Related party transactions

There were no related party transactions in the year.

31

tosis iron

Contact us

We work to support anyone affected by genetic haemochromatosis.

Join us – together we’re stronger Become a member – sign up on our website.

Haemochromatosis UK Advice & Help Line Telephone (12-3pm weekdays): 03030 401 102 Email (24/7): helpline@huk.org.uk

Website: www.haemochromatosis.org.uk Q bjYi Se[5] LEM is bits] i ~~rn”~~ © (|